PM 92114
Alternative Names: D5Latest Information Update: 03 Sep 2002
At a glance
- Originator PharmaMar
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 May 1997 Preclinical development for Cancer in Spain (Unknown route)
- 14 May 1997 Preclinical development for Cancer in USA (Unknown route)
- 17 Apr 1997 No-Development-Reported for Cancer in Spain (Unknown route)